Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 23.68M | 24.38M | 24.75M | 23.85M | 47.39M | 42.68M |
Gross Profit | 10.58M | 10.71M | 11.05M | 11.64M | 19.02M | 20.56M |
EBITDA | -14.01M | -45.89M | -31.92M | -27.30M | -15.72M | -12.30M |
Net Income | -21.32M | -53.95M | -37.66M | -32.90M | -24.83M | -21.82M |
Balance Sheet | ||||||
Total Assets | 33.85M | 36.13M | 43.43M | 68.84M | 67.17M | 82.81M |
Cash, Cash Equivalents and Short-Term Investments | 8.50M | 13.24M | 19.28M | 16.99M | 30.39M | 39.15M |
Total Debt | 28.24M | 24.74M | 23.95M | 39.40M | 23.24M | 52.31M |
Total Liabilities | 75.69M | 82.39M | 82.03M | 73.87M | 53.65M | 61.98M |
Stockholders Equity | -41.84M | -46.26M | -38.60M | -5.03M | 13.52M | 20.83M |
Cash Flow | ||||||
Free Cash Flow | -33.27M | -23.31M | -22.11M | -21.97M | -15.99M | -14.07M |
Operating Cash Flow | -32.79M | -22.66M | -21.76M | -21.43M | -15.62M | -13.44M |
Investing Cash Flow | -1.03M | -474.00K | 14.21M | -540.00K | -369.00K | -640.00K |
Financing Cash Flow | 24.14M | 17.09M | 9.84M | 9.00M | 6.71M | 51.02M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
46 Neutral | $111.09M | -0.73 | ― | ― | -33.76% | 17.10% | |
44 Neutral | $153.02M | -1.40 | -48.76% | ― | 16.55% | 16.73% | |
43 Neutral | $37.53M | ― | 149.62% | ― | -5.22% | 82.06% | |
36 Underperform | $258.18M | -1.66 | ― | ― | ― | -39.69% | |
33 Underperform | $268.58M | -0.13 | ― | ― | ― | -686.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On September 8, 2025, Elutia Inc. entered into an agreement to sell its cardiac implantable electronic device business to Boston Scientific Corporation for $88 million. This transaction is expected to close in the fourth quarter of 2025 and will allow Elutia to focus on its drug-eluting biomatrix solutions in breast reconstruction, strengthen its financial position, and eliminate outstanding debt. The sale marks a strategic shift for Elutia, enabling it to advance its SimpliDerm franchise and drug-eluting pipeline without shareholder dilution, thereby enhancing long-term shareholder value.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.